Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials | News
Search Refinements

Clinical Trials News

View news from other Pharmaceutical sectors:
16-30 of 4090 results
J&J’s prostate cancer drug Zytiga shows significant effect in phase 3 trial
By PBR Staff Writer
Johnson & Johnson’s (J&J) prostate cancer drug Zytiga (abiraterone acetate) has showed a significant effect in the phase 3 LATITUDE clinical trial.
Contract Research & Services > Clinical Trials > News
Teva’s phase 3 study of migraine drug fremanezumab yields positive results
Teva Pharmaceutical Industries has reported positive results from a Phase III HALO study for its migraine drug fremanezumab.
Contract Research & Services > Clinical Trials > News
Lilly’s cyramza succeeds in phase 3 urothelial cancer trial
By PBR Staff Writer
Eli Lilly's Cyramza (ramucirumab), in combination with docetaxel, has succeeded in a phase 3 urothelial cancer trial by meeting its primary endpoint of significantly improving progression-free survival (PFS).
Contract Research & Services > Clinical Trials > News
Lysogene completes patient enrollment in first observational study in MPS IIIA
Biopharmaceutical firm Lysogene has completed enrollment of patients in its “Sanfilippo A Multi-national Observational Study” (SAMOS).
Contract Research & Services > Clinical Trials > News
New drug candidate shown to delay motor neurone disease onset
By PBR Staff Writer
Scientists at the University of Sheffield in the UK have reported encouraging early results in study of a potential drug to combat a form of motor neurone disease.
Contract Research & Services > Clinical Trials > News
Neurocrine’s Ingrezza fails in phase II Tourette syndrome study
Neurocrine Biosciences said that the initial phase II Tourette syndrome T-Force GREEN study of INGREZZA (valbenazine), a small molecule VMAT2 inhibitor, did not meet its primary endpoint.
Contract Research & Services > Clinical Trials > News
Inovio’s HIV vaccine succeeds in early stage trial
Inovio Pharmaceuticals' Pennvax-GP HIV vaccine has demonstrated nearly 100% immune response rates in a clinical study.
Contract Research & Services > Clinical Trials > News
FDA places clinical hold on Concert Pharmaceuticals’ hair loss drug
The US Food and Drug Administration (FDA) has placed a clinical hold on Concert Pharmaceuticals’ CTP-543 Phase 2a clinical trial for alopecia areata.
Contract Research & Services > Clinical Trials > News
Shire’s swelling disorder drug meets primary and secondary endpoints in phase 3 study
By PBR Staff Writer
Shire’s swelling disorder treatment, lanadelumab, has met its primary endpoint and all secondary endpoints in a phase 3 study.
Contract Research & Services > Clinical Trials > News
ImmunoGen unveils promising data with mirvetuximab soravtansine in ovarian cancer
ImmunoGen has reported promising safety and efficacy data from monotherapy and combination trials with mirvetuximab soravtansine in patients with folate receptor alpha (FRα)-positive epithelial ovarian cancer (EOC).
Contract Research & Services > Clinical Trials > News
Aduro Biotech expands clinical collaboration with Merck
Aduro Biotech has expanded its clinical collaboration with Merck to include an additional Phase 2 clinical trial.
Contract Research & Services > Clinical Trials > News
Summit completes patient enrollment in phase 2 trial of ezutromid in DMD
Summit Therapeutics has completed enrolment in PhaseOut DMD, a phase 2 proof of concept clinical trial of ezutromid, in Duchenne muscular dystrophy (DMD) patients.
Contract Research & Services > Clinical Trials > News
Ardelyx reports positive results from phase 3 trial of Tenapanor in IBS-C patients
Ardelyx reported positive, topline results from the T3MPO-1 trial, the first of two Phase 3 trials evaluating tenapanor for the treatment of patients with irritable bowel syndrome with constipation (IBS-C).
Contract Research & Services > Clinical Trials > News
Lilly’s migraine drug galcanezumab succeeds in three phase 3 studies
Eli Lilly's galcanezumab has met its primary endpoint in three phase 3 studies (EVOLVE-1, EVOLVE-2 and REGAIN) showing statistically significant reductions in the number of monthly migraine headache days against placebo at both studied doses.
Contract Research & Services > Clinical Trials > News
AstraZeneca’s Imfinzi meets primary endpoint in phase 3 NSCLC trial
By PBR Staff Writer
AstraZeneca’s Imfinzi (durvalumab) has significantly reduced the risk of disease worsening or death in patients with third stage lung cancer in a phase 3 trial.
Contract Research & Services > Clinical Trials > News
16-30 of 4090 results